Core Viewpoint - PetVivo Holdings, Inc. has entered into a Master Services Agreement with PiezoBioMembrane, Inc. to collaborate on the development of innovative functional biomaterials that can promote tissue and bone regeneration through piezoelectric stimulation [1][2]. Group 1: Partnership Structure and Strategic Benefits - The collaboration aims to combine PetVivo's extracellular matrix (ECM) biomaterial with PiezoBio's piezoelectric nanofibers to create a piezo-biomaterial that enhances healing and regeneration of damaged mammalian tissue and bone [2]. - PiezoBio's biodegradable piezoelectric nanomaterial acts as a battery-less electrical stimulator, providing a novel approach to tissue and bone regeneration [5]. Group 2: Product Development and Innovation - PetVivo has developed a biocompatible biomaterial that mimics mammalian tissue, which is crucial for minimizing adverse effects when implanted in animals or humans [3]. - The company's product SPRYNG® with OsteoCushion® Technology is an intra-articular injectable device that integrates with the animal's subsynovial tissue to restore joint mechanics and manage joint pain [4]. Group 3: Company Overview and Market Strategy - PetVivo focuses on manufacturing and commercializing innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [8]. - The company has a robust pipeline of products protected by twenty-one patents, including SPRYNG™ and PrecisePRP, which are currently available for commercial sale [9].

Core Insights - Digital Landia, in collaboration with PetVivo Holdings and its subsidiary, is set to launch AgenticPet.ai, the first autonomous pet care AI ecosystem, on May 23, 2025, aimed at transforming pet health and wellness through specialized AI agents [1][2] Group 1: Technology and Innovation - AgenticPet.ai utilizes multi-agent technology to create self-learning AI agents that provide insights into pet health, behavior, and nutrition [2][3] - The platform features specialized agents for veterinary diagnostics, behavioral analysis, nutritional advice, emotional wellness, and IoT data integration, enhancing comprehensive pet care [5][4] - The AI agents undergo rigorous digital certification exams to ensure expert-level mastery in various domains related to pet care [3] Group 2: Business Model and Market Strategy - AgenticPet.ai will adopt a tiered pricing structure, including a freemium tier, a premium subscription at $9.95/month, and an elite package at $24.95/month, making the technology accessible to a wide range of pet owners [4][5] - The platform is expected to onboard 100,000 freemium users within six months of launch, with a conservative estimate of a 10% conversion rate to paid subscriptions, potentially generating nearly $2 million in annual recurring revenue [7] Group 3: Strategic Positioning - PetVivo Holdings aims to align its clinically proven therapies with the innovative AI technology of AgenticPet.ai, enhancing its visibility and value in the veterinary care market [8] - The company focuses on leveraging human therapies for companion animals, which allows for a quicker market entry compared to more regulated pharmaceuticals [10]

Core Insights - PetVivo Holdings, Inc. has entered into a distribution agreement with Eq Especialidades to market its veterinary medical device, Spryng with OsteoCushion technology, in Mexico, starting April 1, 2025 [1][3] - Spryng with OsteoCushion technology is designed to manage joint pain in animals by promoting proper joint mechanics and integrating with subsynovial tissue [2][6] - The partnership with Eq Especialidades is expected to enhance PetVivo's market presence in the Mexican animal health sector, benefiting veterinarians and pet owners alike [3] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [5] - The company has a portfolio of 21 patents protecting its biomaterials and products, with lead products including Spryng and PrecisePRP available for commercial sale [6]

Core Viewpoint - PetVivo Holdings, Inc. has secured $5 million in equity financing through a Subscription Agreement, which will support the commercialization of its innovative veterinary medical products [1][4]. Group 1: Financing Details - The company has entered into a Subscription Agreement for $5 million in exchange for five million shares of Series B Convertible Preferred Stock [1]. - The initial proceeds of $600,000 were received on March 26, 2025, with the remaining $4.4 million expected within the next sixty days [1]. Group 2: Product Overview - The funds will be used to advance the commercialization of Spryng with OsteoCushion Technology and PrecisePRP [2][4]. - Spryng is an intra-articular injectable device that integrates with the animal's subsynovial tissue to manage joint pain and conditions like osteoarthritis [2]. - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for easy use by veterinarians, providing a consistent dose of 4 billion platelets per vial [3]. Group 3: Company Strategy and Market Position - PetVivo focuses on leveraging human therapies for companion animals, aiming for a quicker market entry compared to pharmaceuticals [7]. - The company holds a portfolio of twenty-one patents protecting its biomaterials and products, indicating a strong intellectual property position [8].

Core Insights - PetVivo Holdings, Inc. has formed a strategic alliance with Digital Landia Corp. to integrate innovative AI technology into its veterinary products, creating a global pet care ecosystem focused on animal health [1][5] Partnership Structure and Strategic Benefits - PetVivo will invest $150,000 in restricted common stock for a 2% equity stake in Digital Landia, becoming the Platinum Sponsor of the Pet AI community [2] - The partnership includes economic benefits from 3 million Digital Landia tokens, with PetVivo's products being promoted when the AI detects joint-related afflictions in pets [2] Product Overview - SPRYNG® with OsteoCushion® Technology is an injectable veterinary medical device that aids in managing joint pain by restoring proper joint mechanics [3] - PrecisePRP® is a first-in-class, off-the-shelf platelet-rich plasma product designed for easy use by veterinarians, providing a consistent dose of platelets without the need for blood draws [4] Technology and Market Opportunity - Digital Landia's Pet AI platform utilizes self-learning algorithms to analyze animal behavior, achieving 97% accuracy in interpreting animal communication [1][5] - The partnership targets a significant market, with 66% of U.S. households owning pets, initially engaging 123 million American pet owners and expanding internationally [6] Revenue Model and Customer Engagement - The Pet AI platform offers a freemium model and a subscription tier, allowing for tailored learning and improved accuracy through user data [7] - PetVivo will collaborate with veterinarians to deploy AI agents that provide discounts on PetVivo products, enhancing customer loyalty [8] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices for companion animals, leveraging human therapies for efficient treatment [9] - The company has a robust pipeline of products and holds twenty-one patents protecting its biomaterials and methods of use [10]

MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held March 2nd to March 5th, 2025 at the Mandalay Bay Convention Center in Las Vegas, Nevada. PetVivo intends to exhibit its innovative product, SPRYNG® with OsteoCushion® Technology, an intra-articular i ...

MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for equines and companion animals, reported results for its fiscal third quarter ended December 31, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call today at 3:00 p.m. Eastern time to discuss the results for the period (see dial-in information below) ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of ...

MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem’s innovative allogeneic orthobiologic products, PrecisePRP® canine and PrecisePRP® equine. PrecisePRP® is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. It is a leucoreduced, allogeneic, pooled, f ...

MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Friday, February 14, 2025 after market close. The company will host a conference call to discuss these results at 2:00 p.m. CT (3:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materia ...